This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perkins, S. Articles by Gescher, A. J. Search for Related Content PubMed PubMed Citation Articles by Perkins, S. Articles by Gescher, A. J.

Chemopreventive Efficacy and Pharmacokinetics of Curcumin in the Min/+ Mouse, a Model of Familial Adenomatous Polyposis¹

Cancer Biomarkers and Prevention Group, Department of Oncology, University of Leicester, Leicester, LE1 9HN [S. P., R. D. V., K. H., R. A. S., M. L. W., W. P. S., A. J. G.], and Department of Pharmaceutical Sciences, University of Bath, Bath BA2 7AY [I. P., M. D. T.], United Kingdom

Curcumin, the major yellow pigment in turmeric, prevents the development of adenomas in the intestinal tract of the C57Bl/6J Min/+ mouse, a model of human familial APC. To aid the rational development of curcumin as a colorectal cancer-preventive agent, we explored the link between its chemopreventive potency in the Min/+ mouse and levels of drug and metabolites in target tissue and plasma. Mice received dietary curcumin for 15 weeks, after which adenomas were enumerated. Levels of curcumin and metabolites were determined by high-performance liquid chromatography in plasma, tissues, and feces of mice after either long-term ingestion of dietary curcumin or a single dose of [¹⁴C]curcumin (100 mg/kg) via the i.p. route. Whereas curcumin at 0.1% in the diet was without effect, at 0.2 and 0.5%, it reduced adenoma multiplicity by 39 and 40%, respectively, compared with untreated mice. Hematocrit values in untreated Min/+ mice were drastically reduced compared with those in wild-type C57Bl/6J mice. Dietary curcumin partially restored the suppressed hematocrit. Traces of curcumin were detected in the plasma. Its concentration in the small intestinal mucosa, between 39 and 240 nmol/g of tissue, reflects differences in dietary concentration. [¹⁴C]Curcumin disappeared rapidly from tissues and plasma within 2–8 h after dosing. Curcumin may be useful in the chemoprevention of human intestinal malignancies related to Apc mutations. The comparison of dose, resulting curcumin levels in the intestinal tract, and chemopreventive potency suggests tentatively that a daily dose of 1.6 g of curcumin is required for efficacy in humans. A clear advantage of curcumin over nonsteroidal anti-inflammatory drugs is its ability to decrease intestinal bleeding linked to adenoma maturation.

This article has been cited by other articles:

				D. Subramaniam, R. May, S. M. Sureban, K. B. Lee, R. George, P. Kuppusamy, R. P. Ramanujam, K. Hideg, B. K. Dieckgraefe, C. W. Houchen, et al. Diphenyl Difluoroketone: A Curcumin Derivative with Potent In vivo Anticancer Activity Cancer Res., March 15, 2008; 68(6): 1962 - 1969. [Abstract] [Full Text] [PDF]

				N. M. Ramocki, H. R. Wilkins, S. T. Magness, J. G. Simmons, B. P. Scull, G. H. Lee, K. K. McNaughton, and P. K. Lund Insulin Receptor Substrate-1 Deficiency Promotes Apoptosis in the Putative Intestinal Crypt Stem Cell Region, Limits Apcmin/+ Tumors, and Regulates Sox9 Endocrinology, January 1, 2008; 149(1): 261 - 267. [Abstract] [Full Text] [PDF]

				S. Zheng and A. Chen Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-{gamma} in rat hepatic stellate cells Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G113 - G123. [Abstract] [Full Text] [PDF]

				H. Ohori, H. Yamakoshi, M. Tomizawa, M. Shibuya, Y. Kakudo, A. Takahashi, S. Takahashi, S. Kato, T. Suzuki, C. Ishioka, et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol. Cancer Ther., October 1, 2006; 5(10): 2563 - 2571. [Abstract] [Full Text] [PDF]

				D. Chirnomas, T. Taniguchi, M. de la Vega, A. P. Vaidya, M. Vasserman, A.-R. Hartman, R. Kennedy, R. Foster, J. Mahoney, M. V. Seiden, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther., April 1, 2006; 5(4): 952 - 961. [Abstract] [Full Text] [PDF]

				H. Cai, M. Al-Fayez, R. G. Tunstall, S. Platton, P. Greaves, W. P. Steward, and A. J. Gescher The rice bran constituent tricin potently inhibits cyclooxygenase enzymes and interferes with intestinal carcinogenesis in ApcMin mice Mol. Cancer Ther., September 1, 2005; 4(9): 1287 - 1292. [Abstract] [Full Text] [PDF]

				J. Fang, J. Lu, and A. Holmgren Thioredoxin Reductase Is Irreversibly Modified by Curcumin: A NOVEL MOLECULAR MECHANISM FOR ITS ANTICANCER ACTIVITY J. Biol. Chem., July 1, 2005; 280(26): 25284 - 25290. [Abstract] [Full Text] [PDF]

				A. E. Moran, A. M. Carothers, M. J. Weyant, M. Redston, and M. M. Bertagnolli Carnosol Inhibits {beta}-Catenin Tyrosine Phosphorylation and Prevents Adenoma Formation in the C57BL/6J/Min/+ (Min/+) Mouse Cancer Res., February 1, 2005; 65(3): 1097 - 1104. [Abstract] [Full Text] [PDF]

				G. Garcea, D. P. Berry, D. J.L. Jones, R. Singh, A. R. Dennison, P. B. Farmer, R. A. Sharma, W. P. Steward, and A. J. Gescher Consumption of the Putative Chemopreventive Agent Curcumin by Cancer Patients: Assessment of Curcumin Levels in the Colorectum and their Pharmacodynamic Consequences Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 120 - 125. [Abstract] [Full Text] [PDF]

				J. D Lambert, J. Hong, G.-y. Yang, J. Liao, and C. S Yang Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations Am. J. Clinical Nutrition, January 1, 2005; 81(1): 284S - 291S. [Abstract] [Full Text] [PDF]

				R. A. Sharma, S. A. Euden, S. L. Platton, D. N. Cooke, A. Shafayat, H. R. Hewitt, T. H. Marczylo, B. Morgan, D. Hemingway, S. M. Plummer, et al. Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance Clin. Cancer Res., October 15, 2004; 10(20): 6847 - 6854. [Abstract] [Full Text] [PDF]

				P. J. Moos, K. Edes, J. E. Mullally, and F. A. Fitzpatrick Curcumin impairs tumor suppressor p53 function in colon cancer cells Carcinogenesis, September 1, 2004; 25(9): 1611 - 1617. [Abstract] [Full Text] [PDF]

				Curcumin Derivatives: Potential for Prostate Cancer Management: ADDANKI P. KUMAR, GRETCHEN E. GARCIA, RITA GHOSH, RAJENDRAN V. RAJNARAYANAN,1 WILLIAM L. ALWORTH,1 AND THOMAS J. SLAGA, Center for Cancer Causation and Prevention, AMC Cancer Research Center and University of Colorado Comprehensive Cancer Center, Denver, Colorado 80214; 1 Department of Chemistry, Tulane University, New Orleans, Louisiana 70118 Toxicol Pathol, January 1, 2004; 32(1): 161 - 163. [PDF]

				A. H. Conney Enzyme Induction and Dietary Chemicals as Approaches to Cancer Chemoprevention: The Seventh DeWitt S. Goodman Lecture Cancer Res., November 1, 2003; 63(21): 7005 - 7031. [Abstract] [Full Text] [PDF]

				J.-H. Woo, Y.-H. Kim, Y.-J. Choi, D.-G. Kim, K.-S. Lee, J. H. Bae, D. S. Min, J.-S. Chang, Y.-J. Jeong, Y. H. Lee, et al. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt Carcinogenesis, July 1, 2003; 24(7): 1199 - 1208. [Abstract] [Full Text] [PDF]